Psoriatic Arthritis

Peritenon Extensor Tendon Inflammation Associated With Active PsA Enthesitis

Investigators examined the relationship among enthesitis, synovitis, and peritenon extensor tendon inflammation in patients with psoriatic arthritis.

Carotid Ultrasound Improves CV Risk Stratification for Psoriatic Diseases

Investigators evaluated whether subclinical atherosclerosis, as evaluated by carotid ultrasound, is a risk factor for incident cardiovascular events in patients with psoriatic disease.

Efficacy of TNF Agents vs Biologics for PsA-Related Dactylitis and Enthesitis

Researchers examined the efficacy of anti-tumor necrosis factor-a and novel biologic agents to treat dactylitis and enthesitis and compared the results with ACR20 and HAQ scores.

OMERACT Endorses 66/68 Joint Count Measure in Psoriatic Arthritis

OMERACT endorsed the 66/68 swollen and tender joint count SJC66/TJC68 for inclusion in the Core Outcome Measurement Set for patients with psoriatic arthritis.

Primary Endpoints Met in Phase 3 Trials of Guselkumab in Psoriatic Arthritis

Janssen announced positive top-line results from two phase 3 trials of Tremfya (guselkumab) in patients with moderate to severe psoriatic arthritis.

Etanercept-Based Treatments Superior to Methotrexate Monotherapy in PsA

Etanercept monotherapy and combination therapy with etanercept and methotrexate showed greater efficacy than methotrexate monotherapy in patients with psoriatic arthritis.

CV Events, Lipid Level Changes Following Tofacitinib Exposure in PsA

Investigators assessed cardiovascular risk factors and major adverse cardiovascular events in patients with active psoriatic arthritis who received tofacitinib 5 or 10 mg twice daily plus conventional synthetic disease-modifying antirheumatic drugs.

Frequency of Synovitis, Edema Examined in Psoriatic Arthritis

Researchers used ultrasonography to examine whether the duration of psoriatic dactylitis was related to different patterns of extracapsular and synovial-based inflammation.

Long-Term Safety and Efficacy of Apremilast for Psoriatic Arthritis

Researchers evaluated the efficacy and safety of apremilast in patients with psoriatic arthritis.

Safety, Efficacy of the Etanercept Biosimilar SB4 in Psoriatic Arthritis

The etanercept biosimilar SB4 is a cost-effective alternative therapy that can be considered for the treatment of patients with plaque psoriasis and psoriatic arthritis.